India's Piramal Enterprises says gets U.S. nod for new drug trials
Aug 6 (Reuters) - India's Piramal Enterprises Ltd said it has received U.S. regulatory approval to initiate phase I clinical trials for its new drug indicated for lowering lipid and diabetes treatment.
The P7435 molecule has shown significant reduction in triglycerides, blood glucose and insulin levels in pre-clinical studies, the company said in a statement on Tuesday. Its phase I trials will start soon in the United States, it said.
- Obama unveils U.S. immigration reform, setting up fight with Republicans |
- Lawyers descend on Ferguson ahead of grand jury decision
- More arrests as protesters await Ferguson grand jury decision
- U.S., Iran in last-ditch bid to clinch historic nuclear deal
- 'Immoral, but not illegal': metal warehousing games in the spotlight